What is the best treatment for capsular contracture?

Total capsulectomy with implant exchange and, where indicated, a change of plane. That is the consensus answer and it is the operation I most often perform. I want you to understand what supports it. A 2023 systematic review screened 14,163 results, included 34 studies, and found every one of them observational, concluding that there is limited high-level evidence for clear treatment guidelines. Capsulectomy, implant exchange and plane change appear to be useful mechanisms for reducing recurrence. So it is the gold standard by consensus, not by trial. I choose it because the mechanism is coherent, and I say so rather than pretending to a certainty nobody has.

What is the difference between capsulotomy and partial capsulectomy?

They are different operations, and they are confused constantly, even in professional writing. In a capsulotomy the capsule is incised and released, the constricting vectors are divided, and the capsule stays in your body. In a partial capsulectomy, part of the capsule is actually excised and removed. Any biofilm is partly addressed, and the tissue left behind has been proposed as a nidus for recurrence. So one enlarges the pocket without removing anything, and the other removes some of it. If your surgeon uses the two words interchangeably, ask him which he means.

Which Baker grade of capsular contracture needs surgery?

Grades III and IV, generally. Grade I is a soft, natural breast with a quiet capsule. Grade II is minimal firmness that looks entirely normal and that most women do not notice. Grade III is a breast that is firm and visibly distorted, sitting higher and rounder than its neighbor. Grade IV adds pain, and pain is what distinguishes IV from III. So the scale tells us how severe your contracture is. It tells us nothing about which mechanism produced it, and therefore nothing about which operation will best address it. It is vocabulary, not a solution.

Can capsular contracture be treated without surgery?

Rarely, and I would not build a plan around it. A systematic review of non-surgical treatments concluded that the only effective treatment is currently capsulotomy or capsulectomy, with implant removal or a change of plane. The reviewers allowed that a trial of anti-inflammatory medication over some months is a defensible initial measure in a patient reluctant to have surgery and without contraindication. Leukotriene inhibitors such as montelukast are the adjunct with the most interest behind them, and the reported results are promising but heterogeneous. So a capsule that has already contracted is not usually persuaded to relax. I discuss these options with selected patients. I do not promise them.

Does capsular contracture come back after surgery?

It can, and I say so before the first operation rather than after the second. Reported recurrence across the published literature ranges from zero to fifty-four percent. A range that wide is telling you that the studies are not measuring the same thing, in the same patients, over the same interval. It is not telling you your personal risk, and anyone quoting you a precise recurrence figure has read the abstract rather than the paper. So a recurrence is not necessarily evidence that the surgery was wrong. It may be evidence that your biology responds to a foreign body in a way no technique reliably overrides. That is a conversation worth having early.

What is en-bloc capsulectomy and when is it necessary?

It is removal of the implant together with its capsule, as a single unopened specimen. In the whole of this contested literature it is the one place where every author agrees. Where breast implant-associated anaplastic large cell lymphoma is confirmed or suspected, en-bloc capsulectomy is not one option among several. It is the operation. So a breast that swells years after augmentation, without injury and without infection, is investigated before it is operated on. Fluid is aspirated and sent for cytology and CD30 testing. That distinction is made in a laboratory, never by palpation.

How do you decide which capsular contracture operation I need?

Four questions do most of the work, because the evidence will not choose for me. In which plane does your implant currently sit. Was there a hematoma, seroma or infection beforehand. Is this a first contracture or a recurrence. And is there an unexplained late seroma that must be investigated first. Then I weigh the tissue itself. A subglandular implant argues for conversion to a submuscular pocket. A thin, scarred envelope argues against aggressive excision. A calcified capsule argues for taking all of it. So ask me what I would do differently in your case, and why. Surgical appetite is not a substitute for surgical indication.

Capsular Contracture Treatment in Dubai: The Evidence

Dr. Nazmi Baycin, DHA-licensed board-certified plastic surgeon in Dubai

Total capsulectomy with implant exchange and site change is described everywhere as the gold standard for capsular contracture. It is the operation I most often perform. It has never been established by a randomized trial, and when the literature has been pooled, it has not been shown to beat the lesser operation it replaced.

I tell my patients in Dubai this before I tell them anything else, because it explains everything that follows. Capsular contracture is the point at which surgical certainty runs out. What remains is a set of principles, a body of imperfect evidence, and the judgment of the person holding the instrument. This article is about how that judgment is exercised, and about why a surgeon who offers you an algorithm is describing his habits rather than the science.

Key takeaways: what the evidence will and will not tell you

A 2023 systematic review found 34 studies, all observational. Not one randomized trial.
Reported recurrence ranges from 0% to 54% across the published literature.
Pooled data found capsulotomy no worse than capsulectomy for recurrence.
Capsulectomy is the gold standard by consensus, not by trial.
En-bloc capsulectomy for BIA-ALCL is the one point of universal agreement.
Where evidence runs out, judgment begins, and it should be explained to you.

A note on scope. This article concerns a capsule that has already contracted. It does not cover prevention, because everything a surgeon does to prevent contracture happens in theater before the pocket is closed, and because the exercise most patients are told will protect them almost certainly does not; I set that argument out in full in my article on why breast massage does not prevent capsular contracture. What follows begins at the moment prevention has failed.

What the capsule is, and why it turns

Every implant is walled off. The body cannot absorb silicone, so it encircles it with a thin sheath of collagen and leaves it there. In most women that sheath stays quiet, compliant, and invisible for life.

In some it does not. The prevailing model implicates a subclinical bacterial biofilm on the implant surface, most often Staphylococcus epidermidis, provoking a chronic low-grade inflammatory response. That inflammation recruits myofibroblasts, which are fibroblasts that have learned to contract. Collagen is laid down in disordered excess. The sheath tightens, and the breast becomes firm, then spherical, then high-riding, then painful.

Two other factors are consistently implicated. A heightened individual foreign-body response, in which the ordinary healing cascade is amplified beyond what the implant warrants. And hematoma or seroma, which serve simultaneously as a mechanical irritant and as a culture medium.

It is worth saying plainly that the exact mechanism remains unexplained, and that the relative contributions of infection, inflammation and autoimmunity are still contested. The etiology is multifactorial. Anyone who tells you which factor caused yours is guessing.

The Baker scale describes, it does not explain

Clinical severity is graded on the Baker classification, and this remains the language in which the problem is discussed.

Grade I. The breast is soft and appears entirely natural. There is a capsule; there is no contracture.
Grade II. Minimal firmness on examination. The breast still looks normal. The patient often notices nothing.
Grade III. The breast is firm and visibly distorted. It sits higher and rounder than its neighbor.
Grade IV. The breast is hard, distorted, and painful. Pain is what distinguishes IV from III.

Grades III and IV are the ones for which surgery is generally indicated. But note what the scale is: a description of how a breast feels, on a four-point ordinal ranking, assessed by hand. It tells you nothing about which mechanism produced the contracture, and therefore nothing about which operation will best address it. It is the vocabulary of the problem, not the solution to it.

Diagram titled the gold standard that was never tested, noting that capsulectomy is called definitive by consensus and that no randomized trial has ever established it. A section on what the evidence base actually is shows zero randomized trials in any review of surgical management, 34 included studies drawn from 14,163 screened and all observational, a reported recurrence range of 0 to 54 percent across the published literature, and no consensus algorithm, with reviewers unable to favor either operation. A note explains that a pooled comparison of capsulectomy against capsulotomy found recurrence no different between them, and in fact marginally lower after the lesser operation, with the difference not reaching statistical significance. A section comparing three operations shows capsulotomy, in which the capsule is incised and released and nothing is removed, leaving biofilm in place, with the least trauma and lowest bleeding risk, and recurrence no worse in pooled data; partial capsulectomy, in which part of the capsule is excised, distinct from capsulotomy, partly addressing biofilm with intermediate trauma and moderate bleeding risk, where what remains may or may not instigate recurrence; and total capsulectomy, in which the whole capsule is excised with exchange and site change, removing the biofilm with it, carrying the greatest trauma and highest bleeding risk, described as the consensus choice never proven superior in a trial. A panel on the single point of universal agreement explains that where BIA-ALCL is confirmed or suspected, en-bloc capsulectomy is not one option among several but the operation, that every author agrees, and that a late unexplained seroma is investigated before it is operated on and never assumed to be contracture. A section on what decides when the evidence will not lists four questions: in which plane does the implant currently sit, was there a hematoma or seroma or infection, is this a first contracture or a recurrence, and is there a late seroma that must be investigated; alongside what is weighed against the capsule, namely that a subglandular implant argues for a new submuscular home, a thin scarred envelope argues against aggressive excision, a calcified capsule argues for taking all of it, and a patient who wants no further implant argues for explant, concluding that surgical appetite is not a substitute for surgical indication. A panel on non-surgical treatment explains that a trial of anti-inflammatory medication over some months is reasonable in a patient reluctant to undergo surgery and is occasionally rewarded, that leukotriene inhibitors show promising but heterogeneous results, that nothing else has convincing support, and that a capsule which has already contracted is not usually persuaded to relax. A caution panel states that every surgeon presenting a confident stepwise protocol is describing his habits rather than the literature, which contains no such protocol, and that this is a reason to ask how he decides rather than to distrust him. The closing lines read ask your surgeon what he would do differently in your case and why, and that a surgeon who has only one answer has not examined you.

Why the surgical management of capsular contracture rests on consensus rather than on trial evidence — by Dr. Nazmi Baycin, Dubai.

What the evidence base actually is

Before discussing operations, it is worth understanding the quality of the ground we are standing on. It is softer than the confidence of most consultations would suggest.

A systematic review published in 2023 searched MEDLINE, Embase and the Cochrane Database, screened 14,163 results, and ultimately included 34 studies. Every one of them was observational. The authors concluded that there is limited high-level evidence for establishing clear treatment guidelines, and that while capsulectomy, implant exchange and plane change appear to be useful mechanisms for reducing recurrence, more evidence is required.

That is a careful, honest sentence, and it is a very long way from an algorithm.

It gets more uncomfortable. A comparative meta-analysis of capsulectomy against capsulotomy, published as a two-page abstract in a supplement rather than as a full paper, screened 130 articles, selected 21, and found no randomized controlled trial anywhere in the literature. Despite the majority of authors favoring capsulectomy as the gold standard, the pooled recurrence rate was in fact marginally lower after capsulotomy, the lesser operation. The difference was not statistically significant. Neither, the authors observed, is there any consensus algorithm for surgical management.

Reported recurrence is no more settled. A 2016 systematic review that set out to test the gold-standard algorithm directly compared recurrence after open capsulotomy with recurrence after capsulectomy and found them similar: zero to fifty-four percent after the lesser operation, zero to fifty-three percent after the greater one. Its conclusion was that the clinical evidence behind the gold standard is elusive at best. When ranges are that wide, and that alike, they are telling you that the studies are not measuring the same thing in the same patients over the same interval. They are not telling you your risk.

Three operations, and what each leaves behind

There is a persistent confusion, repeated even in professional writing, between capsulotomy and partial capsulectomy. They are not synonyms and they are not the same operation.

Capsulotomy. The capsule is incised and released. The constricting vectors are divided, the pocket enlarges, and the capsule remains in the body. Trauma is least, bleeding is lowest, and any biofilm stays exactly where it was. In pooled data, recurrence is no worse than after the greater operation, which is a finding the profession has largely declined to absorb.
Partial capsulectomy. Part of the capsule is excised. Biofilm is partly addressed and partly retained, and the tissue left behind has been proposed as a nidus for recurrence. Trauma and bleeding sit between the other two.
Total capsulectomy. The entire capsule is excised, ideally as a single specimen, together with implant exchange and, where indicated, a change of plane. The biofilm leaves with the capsule. Trauma is greatest, bleeding risk is highest, and the tissue bed is genuinely new.

I perform total capsulectomy with exchange and site change most often, and I want to be precise about why. Not because a trial demonstrated its superiority, since none has. Because the mechanism is coherent: if a biofilm on an implant surface drives the inflammation, then removing the implant, removing the capsule that harbored it, and rehousing the new device in an untouched, well-vascularized plane addresses the mechanism directly. Coherence is not proof. It is, at present, the best we have — and I should add that the 2016 review above, the one that tested this very algorithm, found the clinical evidence behind it elusive at best. I perform the operation because the mechanism holds, not because the literature compels it.

The operation	What is removed	Biofilm	Trauma	What the evidence says
Capsulotomy	Nothing; capsule released	Left in place	Least	Recurrence no worse, pooled
Partial capsulectomy	Part of the capsule	Partly addressed	Intermediate	Remnant may instigate recurrence
Total capsulectomy	The entire capsule	Removed with it	Greatest	Consensus choice, never trialed
Implant exchange	The device itself	Removed with it	Adds little	Appears useful; I regard it as essential
Site change	Reliance on the old pocket	Bypassed entirely	Moderate	Appears useful for recurrence
En-bloc capsulectomy	Capsule and implant, intact	Contained	Greatest	Universal agreement, for BIA-ALCL

The one point on which everybody agrees

In the whole of this contested literature there is exactly one place where the argument stops.

Where breast implant-associated anaplastic large cell lymphoma is confirmed or suspected, en-bloc capsulectomy, meaning removal of the implant and its capsule together as an unopened specimen, is not one option among several. It is the operation. Every author agrees.

This is why a late seroma matters so much to me, and why I am unwilling to treat it casually. A breast that swells years after augmentation, without injury and without infection, is investigated before it is operated on. Fluid is aspirated and sent for cytology and CD30 immunohistochemistry. It is not assumed to be contracture, and it is not drained and forgotten. The distinction between an inconvenience and a lymphoma is made in a laboratory, not by palpation.

What non-surgical treatment can honestly offer

Patients ask, reasonably, whether the capsule can be persuaded to relax without another operation. Occasionally. Rarely.

A systematic review of non-surgical treatments for established capsular contracture concluded that the only effective treatment is currently capsulotomy or capsulectomy, with implant removal or a change in the plane of insertion, and that the gold standard is the combination of capsulectomy, site change and implant exchange. It allowed that a trial of anti-inflammatory medication over some months is a defensible initial measure in a patient reluctant to undergo surgery and without contraindication. The reviewers noted candidly that very few clinical studies of conservative treatment existed to review at all.

Leukotriene inhibitors, most often montelukast, are the pharmacological adjunct with the most interest behind them, and the results reported to date are promising but heterogeneous. I discuss them with selected patients. I do not promise them. As for closed capsulotomy, the forcible squeezing of the breast to rupture the capsule from outside, I do not perform it. It can rupture the implant, it voids the manufacturer’s warranty, and the contracture very often returns.

How I actually decide

If the evidence will not choose the operation, something must. Four questions do most of the work.

In which plane does the implant currently sit? A subglandular implant with a contracted capsule is the clearest indication I know for total capsulectomy with conversion to a submuscular pocket. The upper pole gains a vascularized muscular barrier it never had.
Was there a hematoma, a seroma, or an infection? If a documented inflammatory event preceded the contracture, the case for removing every gram of capsule that harbored it becomes considerably stronger.
Is this a first contracture or a recurrence? A recurrence after adequate surgery raises the question of whether the tissue bed itself is the problem, and is where I consider acellular dermal matrix as an internal scaffold, or, candidly, whether this patient should carry an implant at all.
Is there an unexplained late seroma? Then nothing above applies until it has been investigated.

Against those answers I weigh the tissue in front of me. A thin, scarred, previously operated envelope argues against aggressive excision, because a capsulectomy performed through inadequate soft tissue can devascularize the very skin it needs. A heavily calcified capsule argues for taking all of it. A patient who has simply had enough argues for breast implant removal in Dubai without replacement, sometimes combined with a breast lift in Dubai to address the envelope that is left. Where a device is still wanted, the conversation becomes one about breast implant exchange in Dubai.

Surgical appetite is not a substitute for surgical indication. The largest operation is not automatically the most rigorous one, and I have come to regard the willingness to perform the smaller operation as the harder discipline.

Recovery, and what recurrence means

Revision for contracture is a more demanding recovery than breast augmentation in Dubai was. The dissection is through scar rather than through virgin tissue. Bleeding is more likely, drains are more often required, and the tissues are less forgiving of impatience. I ask for a defined period of genuine rest and a graduated return to activity, and I watch for inflammation with a vigilance I do not need in a primary case. The physiology of that healing is not incidental, and I have set it out in my article on the science of optimizing surgical recovery.

And it can happen again. I say so before the first operation rather than after the second. A recurrence is not necessarily evidence that the surgery was wrong; it may be evidence that this patient’s biology responds to a foreign body in a way that no technique reliably overrides. That is a different conversation, and it is one worth having early, calmly, and without shame on either side.

Where evidence ends, judgment must be visible

I have spent this article dismantling the certainty with which capsular contracture is usually discussed, and I want to be clear about what that leaves standing.

It leaves a coherent mechanism, a defensible operation that follows from it, and an obligation to say out loud that the operation has never been proven superior in a trial. It leaves the requirement to examine a particular breast, in a particular woman, with a particular history, and to choose. And it leaves the patient entitled to hear the reasoning rather than the conclusion.

So ask your surgeon what he would do differently in your case, and why. Ask what would make him perform the smaller operation. Ask what he does about a late seroma before he touches it. A surgeon who has only one answer has not examined you, and a stepwise protocol offered with total confidence is not a sign of mastery but of a literature not read closely. That is the standard I hold as a leading plastic surgeon in Dubai, and it is why I would rather tell you where the evidence ends than pretend it goes further than it does.

FAQs about capsular contracture treatment in Dubai

What is the best treatment for capsular contracture?

Total capsulectomy with implant exchange and, where indicated, a change of plane. That is the consensus answer and it is the operation I most often perform. I want you to understand what supports it. A 2023 systematic review screened 14,163 results, included 34 studies, and found every one of them observational, concluding that there is limited high-level evidence for clear treatment guidelines. Capsulectomy, implant exchange and plane change appear to be useful mechanisms for reducing recurrence. So it is the gold standard by consensus, not by trial. I choose it because the mechanism is coherent, and I say so rather than pretending to a certainty nobody has.
Is capsulectomy really better than capsulotomy?

Not demonstrably, and this surprises most people. A comparative meta-analysis, published as a conference abstract rather than as a full paper, screened 130 articles, selected 21, and found no randomized controlled trial anywhere in the literature. Despite most authors favoring capsulectomy, the pooled recurrence rate was marginally lower after capsulotomy, the lesser operation. The difference did not reach statistical significance. The authors concluded that no consensus algorithm exists for surgical management. So I still usually perform the larger operation, because removing the implant and the capsule addresses the biofilm mechanism directly. But I regard the willingness to perform the smaller one as the harder discipline.
What is the difference between capsulotomy and partial capsulectomy?

They are different operations, and they are confused constantly, even in professional writing. In a capsulotomy the capsule is incised and released, the constricting vectors are divided, and the capsule stays in your body. In a partial capsulectomy, part of the capsule is actually excised and removed. Any biofilm is partly addressed, and the tissue left behind has been proposed as a nidus for recurrence. So one enlarges the pocket without removing anything, and the other removes some of it. If your surgeon uses the two words interchangeably, ask him which he means.
Which Baker grade of capsular contracture needs surgery?

Grades III and IV, generally. Grade I is a soft, natural breast with a quiet capsule. Grade II is minimal firmness that looks entirely normal and that most women do not notice. Grade III is a breast that is firm and visibly distorted, sitting higher and rounder than its neighbor. Grade IV adds pain, and pain is what distinguishes IV from III. So the scale tells us how severe your contracture is. It tells us nothing about which mechanism produced it, and therefore nothing about which operation will best address it. It is vocabulary, not a solution.
Can capsular contracture be treated without surgery?

Rarely, and I would not build a plan around it. A systematic review of non-surgical treatments concluded that the only effective treatment is currently capsulotomy or capsulectomy, with implant removal or a change of plane. The reviewers allowed that a trial of anti-inflammatory medication over some months is a defensible initial measure in a patient reluctant to have surgery and without contraindication. Leukotriene inhibitors such as montelukast are the adjunct with the most interest behind them, and the reported results are promising but heterogeneous. So a capsule that has already contracted is not usually persuaded to relax. I discuss these options with selected patients. I do not promise them.
Does capsular contracture come back after surgery?

It can, and I say so before the first operation rather than after the second. Reported recurrence across the published literature ranges from zero to fifty-four percent. A range that wide is telling you that the studies are not measuring the same thing, in the same patients, over the same interval. It is not telling you your personal risk, and anyone quoting you a precise recurrence figure has read the abstract rather than the paper. So a recurrence is not necessarily evidence that the surgery was wrong. It may be evidence that your biology responds to a foreign body in a way no technique reliably overrides. That is a conversation worth having early.
What is en-bloc capsulectomy and when is it necessary?

It is removal of the implant together with its capsule, as a single unopened specimen. In the whole of this contested literature it is the one place where every author agrees. Where breast implant-associated anaplastic large cell lymphoma is confirmed or suspected, en-bloc capsulectomy is not one option among several. It is the operation. So a breast that swells years after augmentation, without injury and without infection, is investigated before it is operated on. Fluid is aspirated and sent for cytology and CD30 testing. That distinction is made in a laboratory, never by palpation.
How do you decide which capsular contracture operation I need?

Four questions do most of the work, because the evidence will not choose for me. In which plane does your implant currently sit. Was there a hematoma, seroma or infection beforehand. Is this a first contracture or a recurrence. And is there an unexplained late seroma that must be investigated first. Then I weigh the tissue itself. A subglandular implant argues for conversion to a submuscular pocket. A thin, scarred envelope argues against aggressive excision. A calcified capsule argues for taking all of it. So ask me what I would do differently in your case, and why. Surgical appetite is not a substitute for surgical indication.

dr.nazmi_baycin

🇹🇷🇦🇪Turkish Cosmetic & Plastic Surgeon in Dubai Whatsapp +971 54 7491111
#plasticsurgery #plasticsurgeon #cosmeticsurgery #cosmeticsurgeon #Dubai #UAE

Dr. Nazmi Baycin brings his signature techniques t